Palmetto Peptides Guide to the Research Peptide Tesamorelin
Research Use Only Disclaimer: All information provided in this guide is intended strictly for educational and preclinical research purposes. Tesamorelin sold by Palmetto Peptides is not intended for human or veterinary use, is not a drug or dietary supplement, and has not been approved by the FDA for any clinical application outside of its designated pharmaceutical context. Nothing on this page constitutes medical advice. Researchers are responsible for compliance with all applicable local, state, and federal regulations governing the use of research compounds.
Palmetto Peptides Guide to the Research Peptide Tesamorelin
Tesamorelin is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH) that binds pituitary GHRH receptors with high affinity, stimulates pulsatile GH secretion, and resists enzymatic degradation more effectively than native GHRH — making it a valuable tool in preclinical neuroendocrine research.
This guide covers everything a researcher needs to understand about tesamorelin: its molecular structure, receptor mechanism, comparison to related GHRH analogs, lab handling protocols, quality standards, and research application landscape. If you are evaluating tesamorelin for use in a preclinical study or simply building background knowledge before sourcing, this is the right starting point.
What Is Tesamorelin?
Tesamorelin is a 44-amino acid synthetic peptide that mirrors the complete sequence of human growth hormone-releasing hormone (GHRH), with one key chemical modification at the N-terminal end: the addition of a trans-3-hexenoic acid group. This modification is not cosmetic — it is the structural feature that gives tesamorelin its functional edge over native GHRH in laboratory research settings.
Native GHRH is rapidly cleaved by an enzyme called dipeptidyl peptidase IV (DPP-IV), which snips off the first two amino acids and renders it biologically inactive within minutes. By capping the N-terminus with trans-3-hexenoic acid, tesamorelin sterically blocks DPP-IV from making that cut. The result is a longer-acting, structurally intact GHRH analog that retains full receptor binding capacity and GH-stimulating activity for a meaningfully extended window.
This combination of full sequence retention and enzymatic resistance sets tesamorelin apart from shorter GHRH fragments like sermorelin (GHRH 1-29), which sacrifice some binding surface area, and from albumin-binding analogs like CJC-1295, which extend half-life through a completely different mechanism. For researchers studying the GHRH axis at the receptor level, tesamorelin offers a well-characterized, potent, and stable research tool.
To explore the complete structural rationale behind tesamorelin's design, see Tesamorelin Chemical Structure and Synthesis: What Researchers Need to Know.
A Brief History of Tesamorelin's Development
GHRH itself was not isolated until 1982, when Roger Guillemin and Wylie Vale independently characterized the hormone from pancreatic tumor tissue in patients with acromegaly — a discovery that earned Guillemin a share of the Nobel Prize in Physiology or Medicine. Once the native sequence was known, early research quickly identified the DPP-IV cleavage problem: native GHRH(1-44) had a plasma half-life measured in minutes, which limited its practical utility in both research and clinical contexts.
Through the 1980s and 1990s, structure-activity relationship (SAR) studies mapped which portions of the GHRH sequence were essential for receptor binding. Sermorelin emerged from this work as a truncated analog using only the first 29 residues, the minimum fragment sufficient to activate the GHRH receptor. Separately, Canadian biopharmaceutical company Theratechnologies pursued a different strategy: preserve the full 44-amino acid sequence for maximum receptor engagement and instead protect the N-terminus from DPP-IV cleavage through chemical modification. Their compound, designated TH9507, became what is now known as tesamorelin.
For a detailed timeline of GHRH research milestones leading to tesamorelin, see Tesamorelin History and Development: From GHRH Discovery to Research Use.
How Tesamorelin Works: Receptor Binding and GH Secretion
Understanding tesamorelin at the mechanistic level is essential for designing studies that produce interpretable results. Here is how the signaling cascade unfolds from first contact to hormone release.
GHRH Receptor Binding
Tesamorelin binds to the GHRH receptor (GHRH-R), a G protein-coupled receptor (GPCR) expressed primarily on somatotroph cells in the anterior pituitary. When tesamorelin contacts the receptor, it triggers a conformational change that activates the associated Gs protein. Think of the Gs protein as a molecular ignition switch — when turned, it activates an enzyme called adenylyl cyclase, which converts ATP into cyclic AMP (cAMP).
The cAMP-PKA Cascade
Rising intracellular cAMP acts as a second messenger, activating protein kinase A (PKA). PKA phosphorylates multiple downstream targets, including transcription factors that regulate GH gene expression and ion channels that control membrane potential. As PKA activity builds, the somatotroph membrane depolarizes, opening voltage-gated calcium channels. The resulting calcium influx triggers the exocytosis of pre-formed GH-containing secretory granules.
In plain terms: tesamorelin binds to a receptor, triggers a chain of molecular signals inside the cell, and that chain ends with the pituitary releasing growth hormone in a pulse.
DPP-IV Resistance and Research Implications
Because tesamorelin resists DPP-IV cleavage, it maintains receptor occupancy longer than native GHRH under identical experimental conditions. This translates to more reproducible GH secretion profiles across replicates and more flexibility in dosing window design for animal studies. Researchers can time blood sampling windows with greater confidence that the stimulus compound is still biologically active.
Somatostatin Counterregulation
GH secretion is not purely a function of GHRH receptor activation. Somatostatin, released from the hypothalamus and from delta cells in the pancreas, acts as the opposing signal — binding its own receptors on somatotrophs to suppress GH release. Even with tesamorelin fully engaging GHRH-R, high somatostatin tone can blunt the GH response. This is a critical design variable for in vivo studies; researchers sometimes use somatostatin receptor antagonists or passive immunization protocols to unmask tesamorelin's full stimulatory capacity.
For the full mechanistic breakdown, including receptor desensitization and species-specific considerations, see Tesamorelin Mechanism of Action in Preclinical GHRH Receptor Research Studies.
Tesamorelin vs. Other GHRH Analogs: A Comparison
Researchers working with the GH axis have several GHRH analog options. Choosing the right one depends on the specific research question. The table below summarizes the key structural and functional differences.
| Feature | Tesamorelin | Sermorelin | CJC-1295 |
|---|---|---|---|
| Sequence Length | 44 amino acids (full GHRH) | 29 amino acids (truncated) | 29 amino acids + DAC modification |
| N-Terminal Modification | Trans-3-hexenoic acid | None | Drug Affinity Complex (DAC) |
| DPP-IV Resistance | High | Low | High (via albumin binding) |
| Approximate Half-Life | Hours (extended vs. native) | Minutes (rapidly cleaved) | Days (albumin-bound reservoir) |
| GH Secretion Pattern | Pulsatile, physiological | Pulsatile, shorter duration | Prolonged, blunted pulse amplitude |
| Receptor Desensitization Risk | Moderate (with repeated dosing) | Lower (shorter exposure) | Higher (extended receptor occupancy) |
| Best Research Use Case | Receptor binding studies, pulsatile GH assays, IGF-1 induction | Acute GH response studies, DPP-IV susceptibility comparisons | Long-duration exposure studies, steady-state IGF-1 models |
The choice between these compounds is not simply a matter of potency. If the research question involves studying pulsatile GH secretion in a pattern that approximates endogenous rhythm, tesamorelin is generally a better fit than CJC-1295, which can suppress normal GH pulsatility through prolonged receptor engagement. If the research requires a short-acting standard for comparative work, sermorelin may be more appropriate.
For detailed head-to-head analysis of these compounds, see: - Tesamorelin vs Sermorelin: A Structural and Functional Comparison for Preclinical Research - Tesamorelin vs CJC-1295: Comparing GHRH Analogs for Preclinical Research Applications
Tesamorelin's Chemical Identity
Tesamorelin's molecular weight is approximately 5,135.9 Da. Its amino acid sequence is the complete GHRH(1-44) sequence — Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu (44 residues) — capped at the N-terminal tyrosine with trans-3-hexenoic acid.
Why the Full 44-Residue Sequence Matters
Research in GHRH receptor pharmacology has demonstrated that the C-terminal portion of GHRH (residues 29 to 44) contributes meaningfully to receptor binding affinity, even though the N-terminal region (residues 1 to 29) carries the primary activation determinants. Retaining the full sequence in tesamorelin results in higher receptor binding affinity compared to sermorelin, which may be relevant for studies requiring quantifiable receptor engagement at lower peptide concentrations.
Synthesis and Analytical Characterization
Tesamorelin is produced by solid-phase peptide synthesis (SPPS) using Fmoc chemistry, a stepwise method in which amino acids are assembled on a resin support from C-terminus to N-terminus. After chain assembly and cleavage from the resin, the crude peptide undergoes purification by reverse-phase high-performance liquid chromatography (RP-HPLC) to remove truncated sequences, deletion peptides, and other synthetic impurities. Identity is confirmed by electrospray ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionization (MALDI-MS), which verify the molecular weight of the final product.
For complete synthesis methodology and spectral characterization details, see Tesamorelin Chemical Structure and Synthesis: What Researchers Need to Know.
Purity, Quality Standards, and What to Look for in a Certificate of Analysis
In peptide research, compound quality is not a secondary concern — it is a primary experimental variable. Impure tesamorelin introduces uncontrolled biological signals, compromises data reproducibility, and can make it impossible to attribute observed effects to the intended compound. Every batch of tesamorelin used in rigorous preclinical research should be accompanied by a certificate of analysis (CoA) documenting the following:
Minimum specifications researchers should require:
| Parameter | Minimum Standard |
|---|---|
| HPLC Purity | 98% or higher |
| Molecular Identity | Confirmed by mass spectrometry (ESI or MALDI) |
| Net Peptide Content | Reported as percentage (accounting for water and counterions) |
| Counterion Disclosure | TFA or acetate specified |
| Batch Number | Traceable to a specific production run |
| Appearance | White to off-white lyophilized powder |
It is worth understanding the difference between HPLC purity and net peptide content. A CoA might report 99% HPLC purity — meaning 99% of the UV-absorbing material at 214 nm is the target peptide — but also report 70% net peptide content. The remainder of the mass is water absorbed by the lyophilized powder and TFA counterions from the synthesis process. Both numbers matter: HPLC purity tells you about chemical identity; net peptide content tells you about actual usable peptide mass when calculating working concentrations.
Researchers should be cautious about suppliers who report only one of these values, who do not disclose which analytical method generated the purity figure, or who provide CoAs without traceable batch numbers.
For a complete supplier evaluation framework and CoA assessment guide, see Evaluating Purity and Quality of Tesamorelin Research Peptides and Analytical Testing Methods for High-Purity Tesamorelin in Scientific Research Settings.
Storage, Reconstitution, and Handling
Tesamorelin's primary chemical vulnerability is at methionine residue 27 (Met-27), which is susceptible to oxidation when exposed to oxygen, light, or metal ions. Oxidized methionine changes the peptide's three-dimensional conformation and can reduce receptor binding affinity. Proper storage minimizes this risk.
Storage Conditions
| Form | Recommended Temperature | Shelf Life |
|---|---|---|
| Lyophilized (sealed) | -20°C, dark, dry | Up to 24 months |
| Lyophilized (opened) | -20°C, desiccated | Use within 3 months |
| Reconstituted solution | 4°C, protected from light | 5 to 7 days |
Reconstitution Protocol
The choice of reconstitution solvent matters for tesamorelin stability. Sterile water (USP grade) works for most applications. For peptides that show poor initial solubility, 0.1% to 1% acetic acid can be used as an alternative. DMSO should be avoided, as it does not offer solubility advantages for this peptide and can introduce confounding biological effects in cell-based assays.
A straightforward reconstitution workflow:
- Allow the vial to reach room temperature before opening to prevent moisture condensation on the cold peptide powder.
- Calculate the volume of sterile water needed to achieve your target concentration (account for net peptide content, not gross vial mass).
- Inject the solvent slowly down the inside wall of the vial rather than directly onto the powder.
- Gently swirl — do not vortex or shake, as mechanical agitation can cause aggregation.
- Confirm complete dissolution before withdrawing working aliquots.
- If preparing multiple study sessions, aliquot into single-use volumes before freezing to avoid freeze-thaw cycling.
For the complete protocol with concentration calculation tables, see Tesamorelin Storage, Stability, and Reconstitution for Laboratory Research.
Preclinical Research Applications
Tesamorelin is used across several distinct domains of preclinical neuroendocrine research. The following summarizes the primary application areas.
GHRH Receptor Binding and Signaling Studies
Tesamorelin's well-characterized receptor pharmacology makes it suitable for in vitro receptor binding assays using radiolabeled competition methods, cAMP accumulation assays in somatotroph-derived cell lines (such as GH3), and downstream signaling studies examining PKA activation, CREB phosphorylation, and calcium flux.
Pulsatile GH Secretion Models
In rodent models, tesamorelin reliably stimulates GH secretion in a dose-dependent manner. Because GH is secreted in pulses rather than continuously, researchers studying physiological GH dynamics will find tesamorelin more suitable than long-acting analogs that suppress normal pulsatility. Blood sampling at defined intervals post-administration allows construction of GH secretion profiles.
IGF-1 Axis Studies
Because GH stimulates hepatic IGF-1 production, tesamorelin administration in intact animal models produces measurable downstream IGF-1 elevation. Serum IGF-1 serves as an integrative, temporally stable marker of GH axis activation — particularly useful in chronic or multi-week dosing experiments where capturing individual GH pulses by frequent blood sampling would not be practical.
Comparative GHRH Analog Research
Studies comparing tesamorelin to sermorelin, CJC-1295, or native GHRH can characterize the functional consequences of structural modifications in the GHRH family. This type of structure-activity relationship work contributes to peptide pharmacology knowledge and can inform analog selection for downstream research programs.
GH Axis Interaction Studies
Researchers exploring how somatostatin, ghrelin, and GHRH signals interact at the pituitary level sometimes use tesamorelin in combination with ghrelin mimetics such as Ipamorelin to model synergistic GH secretion. Because GHRH and ghrelin act on distinct receptor populations on the somatotroph, their combined use can reveal cooperative signaling dynamics not visible with either compound alone.
For full application protocols and experimental design guidance, see Tesamorelin Research Applications: Experimental Design and Preclinical Use Cases.
Related Research Peptides in the GH Axis
Tesamorelin research rarely exists in isolation. Researchers studying the somatotropic axis commonly work with a set of related compounds, each of which targets a distinct node in the GH-IGF-1 regulatory network.
GHRH Analogs
- Sermorelin — The 29-amino acid truncated GHRH fragment. Shorter half-life, lower DPP-IV resistance, useful for acute GH response studies and comparative SAR work.
- CJC-1295 — GHRH(1-29) with a DAC modification enabling multi-day half-life through albumin binding. Best suited for long-duration exposure studies where sustained GH axis stimulation is the experimental goal.
Ghrelin Mimetics
- Ipamorelin — A selective GHS-R1a (ghrelin receptor) agonist with high specificity for GH release relative to cortisol and prolactin. Commonly paired with GHRH analogs in combination studies to model synergistic pituitary stimulation.
IGF-1 Axis
- IGF-1 LR3 — A long-acting IGF-1 analog that bypasses the pituitary and acts directly at peripheral IGF-1 receptors. Useful for studying IGF-1 receptor signaling independent of upstream GH axis stimulation, or as a complement to GHRH analog studies.
Tissue Repair Peptides (Adjacent Research)
- BPC-157 — A 15-amino acid peptide studied in preclinical models for its effects on angiogenesis and tissue repair signaling. While not part of the GH axis, it is commonly studied in multimodal regenerative biology protocols.
- TB-500 — A synthetic fragment of thymosin beta-4, studied for actin regulation and tissue repair in preclinical contexts. Often paired with BPC-157 in the Wolverine Stack research model.
Sourcing Tesamorelin for Research: What Matters
Peptide quality in research is not a brand loyalty question — it is a data integrity question. Researchers choosing a tesamorelin source should evaluate it against the following criteria:
Five criteria that define a trustworthy research peptide supplier:
- Batch-specific CoA — Not a generic spec sheet. The CoA should reference the specific lot number of the vial you are receiving, with HPLC chromatogram, MS spectrum, and net peptide content included.
- Third-party testing — Reputable suppliers verify their products through independent analytical laboratories rather than relying solely on in-house data.
- Lyophilized product — Peptides shipped in solution are at higher risk of degradation during transit. Lyophilized powder with cold-chain handling is the appropriate standard.
- Transparent sourcing practices — The supplier should be able to describe their manufacturing standards and testing workflows when asked.
- Research-only compliance — The supplier should operate with clear terms of sale limiting products to research use and should not make therapeutic claims.
Palmetto Peptides Tesamorelin meets these standards, with third-party HPLC and mass spectrometry verification on every batch and batch-specific CoAs available to researchers upon request.
For a complete sourcing evaluation guide including CoA assessment and receiving protocols, see Buying Tesamorelin for Research: Supplier Selection, Purity Standards, and Sourcing Best Practices.
Stability, Shelf Life, and Long-Term Study Planning
Peptide degradation in the laboratory is a silent threat to experimental validity. Tesamorelin that has partially degraded before an experiment begins produces lower GH responses than the researcher expects, creating variability that may be misattributed to biological factors rather than compound quality.
The primary degradation mechanisms for tesamorelin are:
- Methionine oxidation — The most common failure mode. Occurs with oxygen exposure, metal ion contamination, or improper storage. Produces a +16 Da mass shift visible on mass spectrometry. Oxidized Met-27 variants have reduced receptor binding affinity.
- Peptide bond hydrolysis — Occurs in aqueous solution, particularly at elevated temperatures or extreme pH. This is why reconstituted tesamorelin has a short refrigerated shelf life.
- Aggregation — Physical association of multiple peptide molecules into non-functional clumps. Promoted by mechanical shaking, freeze-thaw cycling, and long-term storage of reconstituted solutions.
Researchers planning multi-week or multi-month studies should acquire enough lyophilized peptide to support the full study timeline, prepare fresh reconstituted working solutions rather than storing large volumes at 4°C, and retain a small reference aliquot of each batch for analytical re-verification if unexpected biological results emerge mid-study.
For full shelf life data tables and degradation monitoring guidance, see Tesamorelin Shelf Life and Long-Term Stability for Multi-Week Preclinical Studies and Analytical Testing Methods for High-Purity Tesamorelin in Scientific Research Settings.
Regulatory and Compliance Summary
Tesamorelin is a research compound. In the United States, it is legally available for purchase by researchers for in vitro and preclinical research purposes. It is not approved for over-the-counter distribution for human use, and Palmetto Peptides does not represent it as such.
All tesamorelin purchased through Palmetto Peptides is sold under research-only terms. Purchasers agree that the compound will be used in legitimate scientific research contexts and will not be administered to humans or animals outside of approved institutional protocols. Researchers are responsible for compliance with all applicable institutional, state, and federal regulations governing research compound use, including IACUC requirements for animal research.
No information on this page, or anywhere on the Palmetto Peptides website, constitutes medical advice, a treatment recommendation, or a suggestion of therapeutic use.
Frequently Asked Questions
What is tesamorelin used for in preclinical research? Tesamorelin is used as a pharmacological tool to activate GHRH receptors on pituitary somatotroph cells in preclinical laboratory models. Research applications include GHRH receptor binding studies, GH secretion dynamics, IGF-1 axis modulation, and comparative GHRH analog pharmacology. All Palmetto Peptides tesamorelin is for research use only.
How does tesamorelin compare to other GHRH analogs in terms of receptor binding? Tesamorelin retains the full 44-amino acid GHRH sequence, giving it a larger receptor contact surface than the 29-residue sermorelin. Combined with its DPP-IV resistance from the N-terminal trans-3-hexenoic acid modification, this makes tesamorelin a higher-affinity, more stable receptor ligand for preclinical study designs requiring reproducible, sustained GHRH-R engagement.
Can tesamorelin be used in combination with ghrelin mimetics in research? Yes. In preclinical research, tesamorelin is sometimes used alongside ghrelin receptor agonists like ipamorelin to model synergistic GH secretion. GHRH and ghrelin activate distinct receptor populations on the somatotroph, and their combined use can reveal additive or superadditive GH release dynamics not observable with either compound alone.
What analytical methods confirm tesamorelin identity? Reverse-phase HPLC confirms purity by separating the target peptide from impurities. Electrospray ionization mass spectrometry (ESI-MS) or MALDI-MS confirms molecular identity by verifying the molecular weight (approximately 5,135.9 Da). Amino acid analysis (AAA) can serve as an orthogonal confirmation of composition.
What is the difference between HPLC purity and net peptide content on a CoA? HPLC purity reflects the proportion of UV-absorbing material that is the target peptide, typically measured at 214 nm. Net peptide content accounts for the actual peptide mass relative to the total vial weight, which includes absorbed water and TFA or acetate counterions from synthesis. A vial can show 99% HPLC purity but only 70% to 80% net peptide content. Researchers need both numbers to calculate accurate working concentrations.
How long does reconstituted tesamorelin remain stable? Reconstituted tesamorelin should be used within 5 to 7 days when stored at 4°C and protected from light. Stability declines beyond this window due to peptide bond hydrolysis and oxidation. For studies requiring preparation in advance, aliquoting and freezing at -20°C immediately after reconstitution extends usable life, though each freeze-thaw cycle introduces some degradation risk.
Where can I purchase tesamorelin for preclinical research? Palmetto Peptides offers tesamorelin with third-party HPLC and MS verification, batch-specific CoAs, and research-only terms of sale. The product is lyophilized and handled with cold-chain protocols to support laboratory-grade stability upon receipt.
Summary: Tesamorelin as a Preclinical Research Tool
Tesamorelin occupies a well-defined position in the GHRH analog research landscape. Its full 44-amino acid sequence provides broad receptor contact surface. Its N-terminal modification blocks DPP-IV cleavage. Together, these features produce a compound that engages GHRH receptors more stably and reproducibly than native GHRH, and with a more physiological GH secretion profile than ultra-long-acting albumin-binding analogs.
For researchers designing studies around the GH-IGF-1 axis, tesamorelin offers flexibility across multiple experimental levels: receptor pharmacology in cell systems, pulsatile GH secretion studies in rodent models, IGF-1 induction in chronic dosing protocols, and comparative GHRH analog characterization. Combined with rigorous quality sourcing and proper laboratory handling, it is a reliable research compound for neuroendocrine studies.
Explore the complete Tesamorelin Research Cluster for deeper coverage of individual topics:
- Tesamorelin Mechanism of Action
- Tesamorelin Chemical Structure and Synthesis
- Tesamorelin vs Sermorelin
- Tesamorelin vs CJC-1295
- Tesamorelin History and Development
- Tesamorelin Storage, Stability, and Reconstitution
- Evaluating Purity and Quality of Tesamorelin Research Peptides
- Tesamorelin Preclinical Findings on GH Secretion
- Buying Tesamorelin for Research
- Tesamorelin Research Applications
- Tesamorelin Shelf Life and Long-Term Stability
- Analytical Testing Methods for Tesamorelin
References
Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. Journal of Clinical Investigation. 1989;83(5):1533-1540. doi:10.1172/JCI114050
Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
Laferrere B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology and Metabolism. 2005;90(2):611-614. doi:10.1210/jc.2004-1719
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology: Endocrinology and Metabolism. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
Bhatt DL, Bhattacharya S, Boden WE. Treatment of obesity and weight-related cardiovascular risk factors. NEJM Evidence. 2022. [Context: GHRH biology referenced in metabolic endocrinology literature.]
Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet. 2000;356(9236):1137-1142. doi:10.1016/S0140-6736(00)02755-X
Author: Palmetto Peptides Research Team Last Updated: April 5, 2026
This content is produced for educational and scientific research informational purposes only. Tesamorelin sold by Palmetto Peptides is not intended for human or veterinary use. Nothing on this page constitutes medical advice or a treatment recommendation. Researchers are responsible for full compliance with applicable regulations governing research compound use.